title: Transgenic animals in experimental xenotransplantation models: orthotopic heart transplantation in the pig-to-baboon model.
abstract: Pig organs are at risk for hyperacute and acute vascular rejection mediated by anti-pig antibodies, mainly binding to the Galalpha(1,3)Gal epitope. Acute cellular rejection is characterized by progressive infiltration of mononuclear cells. There is an ongoing search for immunosuppressive regimens that provide adequate protection against all patterns of xenograft rejection, but have no severe impact on the condition of xenograft recipients. Herein orthotopic heart transplantations were performed from hDAF or hCD46 piglets to nonsplenectomized baboons. Basic immunosuppression consisted of tacrolimus, sirolimus, GAS914, steroids, and ATG. Group 1 received basic immunosuppression. Group 2 was additionally treated with rituximab and group 3 with half-dose cyclophosphamide. Group 4 received cyclophosphamide and an anti-HLA-DR antibody. Three baboons received GAS914 and TPC. Monitoring included the regular assessment of anti-porcine antibodies, blood counts, therapeutic drug monitoring, and graft histology. Two grafts failed due to technical mistakes. In group 1, baboons died after 1 and 9 days. In group 2, maximum survival was 30 hours. In group 3, baboons lived 20 hours, 25 days, and 14 days. Group 4 survival times were 9.5 hours, 5.5 hours, 4 days, 34 hours, and 3 days. An increase of non-Galalpha(1,3)Gal antibodies was observed. Depositions of immunoglobulins and complement revealed a humoral rejection process. No cellular infiltration could be observed. In conclusion, suppressing cellular rejection with half-dose cyclophosphamide together with tacrolimus and sirolimus produced longer graft survival with a good general condition. Prevention of acute xenograft rejection further needs inhibition of non-Galalpha(1,3)Gal cytotoxicity by sufficient depression of B-cell activation.
authors.affiliation: Department of Cardiac Surgery, Institute for Surgical Research, Clinic for Anaesthesiology, and the Institute for Pathology, Ludwig-Maximilians-University of Munich, Munich, Germany. urbrandl@med.uni-muenchen.de
authors.forename: U
authors.initials: U
authors.lastname: Brandl
authors.forename: S
authors.initials: S
authors.lastname: Michel
authors.forename: M
authors.initials: M
authors.lastname: Erhardt
authors.forename: P
authors.initials: P
authors.lastname: Brenner
authors.forename: L
authors.initials: L
authors.lastname: Burdorf
authors.forename: H
authors.initials: H
authors.lastname: Jöckle
authors.forename: I
authors.initials: I
authors.lastname: Bittmann
authors.forename: M
authors.initials: M
authors.lastname: Rössle
authors.forename: V
authors.initials: V
authors.lastname: Mordstein
authors.forename: H
authors.initials: H
authors.lastname: Baschnegger
authors.forename: A
authors.initials: A
authors.lastname: Bauer
authors.forename: C
authors.initials: C
authors.lastname: Hammer
authors.forename: B
authors.initials: B
authors.lastname: Reichart
authors.forename: M
authors.initials: M
authors.lastname: Schmoeckel
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D018958:CD55 Antigens / Q000235:genetics*; D006085:Graft Survival; D016027:Heart Transplantation / Q000502:physiology*; D006801:Humans; D010215:Papio; D013552:Swine; D014183:Transplantation, Heterologous / Q000502:physiology*
chemical_list: D018958:CD55 Antigens